Home Cart Sign in  
Chemical Structure| 857064-38-1 Chemical Structure| 857064-38-1

Structure of WP1066
CAS No.: 857064-38-1

Chemical Structure| 857064-38-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

WP1066 is an inhibitor of JAK2 and STAT3 and also affects STAT5 and ERK1/2, without impacting JAK1 and JAK3.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of WP1066

CAS No. :857064-38-1
Formula : C17H14BrN3O
M.W : 356.22
SMILES Code : O=C(N[C@H](C1=CC=CC=C1)C)/C(C#N)=C/C2=NC(Br)=CC=C2
MDL No. :MFCD12912450
InChI Key :VFUAJMPDXIRPKO-LQELWAHVSA-N
Pubchem ID :11210478

Safety of WP1066

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of WP1066

epigenetics
RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • JAK2

    JAK2, IC50:2.3 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
B16 cells 0, 0.156, 0.313, 0.625, 1.25, 2.5, 5.0 µM 72 h To evaluate the direct cytotoxic effects of WP1066 on B16 cells, results showed that WP1066 enhanced tumor cytotoxicity when combined with CTX. PMC3319790
B16 cells 2.5 µM, 5 µM 2 h To evaluate the inhibitory effect of WP1066 combined with CTX on p-STAT3, results showed that CTX enhanced the inhibition of p-STAT3 by WP1066. PMC3319790
D283-Med cells 10 µM 48 h To evaluate the effect of WP1066 on the STAT3 signaling pathway, results showed that WP1066 significantly reduced the expression of p-STAT3 and c-MYC. PMC8357694
CT2A cells 10 μM To verify the effect of STAT3 inhibitor WP1066 on CT2A cells, results showed that WP1066 treatment reduced YAP1 expression. PMC10914854
GL261 cells 10 μM To verify the effect of STAT3 inhibitor WP1066 on GL261 cells, results showed that WP1066 treatment reduced YAP1 expression. PMC10914854
GSC272 cells 10 μM To verify the effect of STAT3 inhibitor WP1066 on GSC272 cells, results showed that WP1066 treatment reduced YAP1 expression. PMC10914854
PANC-1 cells 5 μM 24 h To study the inhibitory effect of WP1066 on the STAT3 signaling pathway, results showed that WP1066 effectively inhibited STAT3 activation and reduced LOXL2 expression. PMC11745814
SW1990 cells 5 μM 24 h To study the inhibitory effect of WP1066 on the STAT3 signaling pathway, results showed that WP1066 effectively inhibited STAT3 activation and reduced LOXL2 expression. PMC11745814
GL261 cells 0, 1.56, 3.13, 6.25, 12.5, 25 μM 72 h To evaluate the effect of WP1066 on the proliferation and survival of GL261 cells, and to calculate the IC50 value. PMC9341321
hepatocytes 5 μM 24 h To evaluate the inhibitory effect of WP1066 on STAT3 phosphorylation, the results showed that WP1066 significantly inhibited STAT3 phosphorylation. PMC9431681
KYSE30 5 μM 20 h To investigate the effect of WP1066 on STAT3-mediated EMT in MAGE-C3 overexpressing KYSE30 cells. Results showed that WP1066 treatment attenuated the promotion of migration and invasion by MAGE-C3. PMC8696229
KYSE410 5 μM 20 h To investigate the effect of WP1066 on STAT3-mediated EMT in MAGE-C3 overexpressing KYSE410 cells. Results showed that WP1066 treatment attenuated the promotion of migration and invasion by MAGE-C3. PMC8696229

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice intracerebral B16 melanoma model oral 30 mg/kg once every other day for 9 treatments To evaluate the therapeutic efficacy of WP1066 combined with CTX against intracerebral melanoma, results showed that the combination significantly prolonged the survival of mice. PMC3319790
Mice Ischemic stroke model Intraperitoneal injection 30 mg/kg Once daily for 5 days WP1066, as a STAT3 inhibitor, was used to study its neuroprotective effects in the ischemic stroke model. The results showed that WP1066 suppressed Li+-induced activation of STAT3, thereby affecting UCP2 expression and ROS production. PMC8814028
Rats Pilocarpine-induced status epilepticus model Intraperitoneal injection 50 mg/kg Two doses, 45 minutes apart WP1066 transiently inhibits pSTAT3 after the onset of status epilepticus and reduces long-term spontaneous seizure frequency, but does not affect status epilepticus or cell death. PMC3908775
NOD scid gamma mice MBGroup3 mouse model Intraperitoneal injection 30 mg/kg Every other day for 24 days To evaluate the effect of combined treatment with WP1066 and CQ on the MBGroup3 mouse model, results showed that the combined treatment significantly extended the survival of mice. PMC8357694
Mice CT2A tumor model Oral 60 mg/kg Every other day for 6 doses To verify the effect of STAT3 inhibitor WP1066 on the CT2A tumor model, results showed that WP1066 treatment reduced plasma levels of CCL2 and CCL7 and decreased intratumoral macrophages. PMC10914854
C57BL/6 mice GL261 glioma model Oral gavage 60 mg/kg Monday, Wednesday, Friday for 3 weeks To evaluate the therapeutic effect of WP1066 combined with whole-brain radiation therapy (WBRT) on glioma, the results showed that the combination therapy significantly prolonged the survival of mice and induced immunological memory. PMC9341321

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01904123 Metastatic Malignant Neoplasm ... More >>in the Brain Metastatic Melanoma Recurrent Brain Neoplasm Recurrent Glioblastoma Recurrent Malignant Glioma Less << Phase 1 Recruiting July 31, 2021 United States, Texas ... More >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Amy B. Heimberger    713-563-8717       Principal Investigator: Amy B. Heimberger Less <<
NCT04334863 Brain Tumor|Medulloblastoma|Br... More >>ain Metastases Less << PHASE1 COMPLETED 2023-02-03 Children's Healthcare of Atlan... More >>ta (CHOA), Atlanta, Georgia, 30322, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.81mL

0.56mL

0.28mL

14.04mL

2.81mL

1.40mL

28.07mL

5.61mL

2.81mL

References

[1]Tsurumaki H, Katano H, Sato K, Imai R, Niino S, Hirabayashi Y, Ichikawa S. WP1066, a small molecule inhibitor of the JAK/STAT3 pathway, inhibits ceramide glucosyltransferase activity. Biochem Biophys Res Commun. 2017 Sep 16;491(2):265-270. doi: 10.1016/j.bbrc.2017.07.115. Epub 2017 Jul 21. PMID: 28739255.

[2]Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res. 2008 Feb 1;14(3):788-96. doi: 10.1158/1078-0432.CCR-07-0524. PMID: 18245540.

[3]Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res. 2007 Dec 1;67(23):11291-9. doi: 10.1158/0008-5472.CAN-07-0593. PMID: 18056455.

[4]Hatiboglu MA, Kong LY, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W, Heimberger AB. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer. 2012 Jul 1;131(1):8-17. doi: 10.1002/ijc.26307. Epub 2011 Aug 24. PMID: 21792892; PMCID: PMC3319790.

[5]Geng L, Li X, Zhou X, Fang X, Yuan D, Wang X. WP1066 exhibits antitumor efficacy in nasal‑type natural killer/T-cell lymphoma cells through downregulation of the STAT3 signaling pathway. Oncol Rep. 2016 Nov;36(5):2868-2874. doi: 10.3892/or.2016.5091. Epub 2016 Sep 15. PMID: 27633398.

 

Historical Records

Categories